Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2000-06-19
2002-11-05
Beckerleg, Anne Marie S. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S455000, C435S325000
Reexamination Certificate
active
06475999
ABSTRACT:
BACKGROUND OF THE INVENTION
Numerous attempts have been made to modulate a host's immune system as a means for treating cancers. Such attempts include: active immunotherapy using tumor or tumor antigen containing vaccines or immure active lymphokines; adoptive immunotherapy using a host's peripheral blood or tumor infiltrating lymphocytes expanded in culture and reinjected; passive immunotherapy by administration of monoclonal antibodies; and localized immunotherapy using intralesional administration of agents such as Bacillus Calmette-Guerin (BCG). The most effective of these approaches has been localized therapy with BCG for melanoma metastasis to the skin and superficial bladder cancer. While the mechanism of action of BCG is not completely understood, studies clearly show that successful immunotherapy of this type is associated with recruitment of T cells to the tumor.
Cytokines such as the interleukins are important mediators in cell-mediated immune responses in a host. The cell-mediated immune response (“local immune response”) is produced by thymus derived lymphocytes or T-cells. T-cells detect the presence of invading pathogens through a recognition system referred to as the T-cell antigen receptor. Upon detection of an antigen, T-cells direct the release of multiple T-cell lymphokines including, but not limited to, the interleukin-2 family (IL-2). IL-2 is a T-cell growth factor which promotes the production of many more T-cells sensitive to the particular antigen. This production constitutes a clone of T-cells. The sensitized T-cells attach to cells containing the antigen. T-cells carry out a variety of regulatory and defense functions and play a central role in immunologic responses. When stimulated to produce a cell-mediated immune response, some T-cells respond by acting as killer cells, killing the host's own cells when these have become infected with virus and possibly when they become cancerous and therefore foreign. Some T-cells respond by stimulating B cells while other T-cells respond by suppressing immune responses.
Examples of other interleukins which are mediators in cell-mediated immune responses include interferon-&ggr; (IFN-&ggr;), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-4 (IL-4), interleukin-5 (IL-5) and interleukin-12 (IL-12). IFN-&ggr; activates macrophages and enhances expression of immune-reactive antigens on tumor cells. GM-CSF activates macrophages and stimulates macrophage and dendrite cell recruitment and differentiation. IL-4 is a T cell derived helper lymphokine which participates in the regulation of growth and differentiation of B and T cells. IL-5 is a T cell derived lymphokine which has its primary effects on the expansion of eosinophils. There is evidence which suggests that eosinophils, when recruited to a tumor site, may have direct anti-tumor effects. IL12 is a heterodimeric lymphokine initially purified from the conditioned medium of a human B lymphoblastoid cell line. Murine IL-12 has now been cloned and expressed. IL-12 stimulation has been shown to enhance antigen presentation and the cytolytic activity of natural killer cells.
The value of cytokine-based gene therapy was suggested in preclinical murine studies. Inoculation of mice with experimental tumors transfected with genes for tumor necrosis factor (Asher AL, et al.,
J. Immunol
. 1991 146:3227), interleukin-2 (Fearon E R, et al.,
Cell
1990 60:397), and IL-4 (Golumbek P T, et al.,
Science
1991 254:713) resulted in growth and subsequent rejection of the injected tumor. In many cases the mice were shown to generate a systemic anti-tumor response. IL-4 transfected tumors regressed and lead to the regression of admixed non-transfected tumors in mice (Tepper P I, et al.,
Cell
1989 57:503). This immunotherapy was also effective in nu
u mice demonstrating a non-T cell component which may contribute to localized therapy. IL-4 transfected RENCA cells have been shown to generate specific T cell immunity to the tumor, and result in elimination of pre-existing non-local tumor growth (Golumbek P T, et al.,
Science
1991 254:713).
Current approaches to this form of therapy involve the growth and stabile gene modification of tumor cells to produce cytokines, their expansion in vitro, and reinjection into the host. While this type of therapy may be feasible in experimental systems, the lack of ability to grow the majority of tumors in vitro, the requirements for in vitro genetic modification of each patient's tumor, and the reinjection of viable tumor into the patient limit the clinical applicability of the approach.
It has now been found that expression of immune active cytokines in tumors can be induced in situ by administration of a vaccinia virus vector. These vaccinia virus vectors can be administered to animals suffering from cancer as a treatment. The vaccinia virus vectors of the present invention are also useful in enhancing immunity to parasites and other invading pathogens which alone fail to invoke an effective host immune response.
SUMMARY OF THE INVENTION
An object of the present invention is to provide a method of inducing expression of immune active cytokines in tumors in situ which comprises generating a vaccinia virus vector capable of inducing expression of a selected cytokine and injecting the vaccinia virus vector into a tumor so that cells of the tumor express the selected cytokine.
Another object of the present invention is to provide a method of enhancing immunity in a host which comprises generating a vaccinia virus vector capable of inducing expression of a selected cytokine and injecting the vaccinia virus vector into a host so that cells of the host express the selected cytokine.
A final object of the present invention is to provide a method of treating cancer which comprises administering to an animal suffering from cancer an amount of a vaccinia virus vector capable of inducing an immune response to the cancer in the animal.
REFERENCES:
patent: 5017487 (1991-05-01), Stunnenberg et al.
patent: 5597570 (1997-01-01), Stunnenberg et al.
patent: 6093700 (2000-07-01), Mastrangelo
patent: 64279/94 (1995-10-01), None
patent: 0206920 (1986-12-01), None
patent: 0268501 (1988-05-01), None
patent: 0514603 (1992-11-01), None
patent: 0753581 (1997-01-01), None
patent: WO 920526 (1992-04-01), None
patent: WO 9421792 (1994-02-01), None
patent: WO 9421808 (1994-02-01), None
patent: WO 9408601 (1994-04-01), None
patent: WO 9416716 (1994-08-01), None
patent: WO 9421798 (1994-09-01), None
patent: WO 9509241 (1995-04-01), None
patent: WO 8800971 (1998-02-01), None
patent: 9402636 (1994-11-01), None
Irvine et.al.; Cytokine Enhancement of DNA Immunization Leads to Effective Treatment of Established Pulmonory Metastasees, 1996, Journal of Immunology 156: 238-245.*
Bronte et.al.; IL-2 Enhances the Function of Recombinant Poxvirus-Based Vaccines in the Treatment of Established Pulmomory Metastases, 1995, Journal of Immunology 154: 5282-5292.*
Bash et al. (1993) Journal of Immunotherapy. vol. 14, 269-272.*
Ramshaw et al. (1992) Immunological Reviews. vol. 127, 157-182.*
Pincus et al. (1995) Biologicals. vol. 23, 159-164.*
Orkin et al. (1995) “Report and recommendations of the panel to assess the NIH investment in research on gene therapy”.*
Ross et al. (Sep. 1996) Human Gene Therapy, vol. 7, 1781-1790.*
Bachmann et al. (1994) Current Opinion in Immunology, vol. 6, 320-326.*
Vieweg et al. (1995) Cancer Investigation, vol. 13(2), 193-201.*
James et al. (1991) Antiviral Chem. & Chemotherapy, vol. 2, 191-214.*
Branch (1998) TIBS, vol. 23, 45-50.*
Corcoran, et al.: “GM-CSF Produced by Recombinant Vaccina Virus or in GM-CSF Transgenic Mice Has no Effect in-vivo on Murine Cutaneous Leishmaniasis”,Journal of Parasitology, vol. 74, No. 5, 1988, pp. 763-767.
Qin Hongxin, et al.: “Vaccina Virus as Vector for Cancer Gene Therapy”,Proceedings of the American Association for Cancer Research Annual, vol. 36, Mar. 1995, p. 418.
Lee, et al.: “In vivo Gene Therapy of Murine Tumors Using Recombinant Vaccina Virus Encoding GM-CSF.”Proceedings of
Berd David
Eisenlohr Laurence C.
Lattime Edmund C.
Mastrangelo Michael J.
Beckerleg Anne Marie S.
Drinker Biddle & Reath LLP
Thomas Jefferson University
LandOfFree
Method of inducing an immune response using vaccinia virus... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inducing an immune response using vaccinia virus..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inducing an immune response using vaccinia virus... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2987353